[
  {
    "ts": null,
    "headline": "AMD & Pfizer earnings, ISM services data: What to Watch",
    "summary": "Market Domination Overtime host Josh Lipton takes a look at the top stories for investors to watch on Tuesday, Aug. 5. In the morning, Caterpillar (CAT) and Pfizer (PFE) will announce earnings results. Advanced Micro Devices (AMD), Amgen (AMGN), Snap (SNAP), and Rivian (RIVN) will announce results in the afternoon. In the morning, Institute for Supply Management (ISM) services data for July will be released. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.",
    "url": "https://finnhub.io/api/news?id=5a59ed8c6f508eb060cb2792abddcbf0e98a05faba69aeee0b9a8a5de103d33f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754348400,
      "headline": "AMD & Pfizer earnings, ISM services data: What to Watch",
      "id": 136205791,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Market Domination Overtime host Josh Lipton takes a look at the top stories for investors to watch on Tuesday, Aug. 5. In the morning, Caterpillar (CAT) and Pfizer (PFE) will announce earnings results. Advanced Micro Devices (AMD), Amgen (AMGN), Snap (SNAP), and Rivian (RIVN) will announce results in the afternoon. In the morning, Institute for Supply Management (ISM) services data for July will be released. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.",
      "url": "https://finnhub.io/api/news?id=5a59ed8c6f508eb060cb2792abddcbf0e98a05faba69aeee0b9a8a5de103d33f"
    }
  },
  {
    "ts": null,
    "headline": "Selloff? What Selloff? Monday Market Rebound",
    "summary": "Palantir is way up after reporting Q2 results Monday afternoon, while HIMS and VRTX are way off highs.",
    "url": "https://finnhub.io/api/news?id=991417c1a9324c195c00aa69826dc864befea84783e1e883ddc9c524f9f5ff88",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754345880,
      "headline": "Selloff? What Selloff? Monday Market Rebound",
      "id": 136205827,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Palantir is way up after reporting Q2 results Monday afternoon, while HIMS and VRTX are way off highs.",
      "url": "https://finnhub.io/api/news?id=991417c1a9324c195c00aa69826dc864befea84783e1e883ddc9c524f9f5ff88"
    }
  },
  {
    "ts": null,
    "headline": "Acadia Pharmaceuticals Appoints Scott Cenci as Chief Information and Data Officer",
    "summary": "SAN DIEGO, August 04, 2025--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Scott Cenci as Senior Vice President, Chief Information and Data Officer. In this role, Scott will lead Acadia’s digital transformation including technology, data and AI strategy and will serve as a member of the company’s Executive Leadership Team, reporting to Catherine Owen Adams, Chief Executive Officer of Acadia.",
    "url": "https://finnhub.io/api/news?id=6652e78474b5c4bf59d987303e5ca8a2962d636cb97dc23ed02e63a29b4bd9b4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754337900,
      "headline": "Acadia Pharmaceuticals Appoints Scott Cenci as Chief Information and Data Officer",
      "id": 136205893,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "SAN DIEGO, August 04, 2025--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Scott Cenci as Senior Vice President, Chief Information and Data Officer. In this role, Scott will lead Acadia’s digital transformation including technology, data and AI strategy and will serve as a member of the company’s Executive Leadership Team, reporting to Catherine Owen Adams, Chief Executive Officer of Acadia.",
      "url": "https://finnhub.io/api/news?id=6652e78474b5c4bf59d987303e5ca8a2962d636cb97dc23ed02e63a29b4bd9b4"
    }
  },
  {
    "ts": null,
    "headline": "Viatris Poised to Report Q2 Earnings: What's in Store for the Stock?",
    "summary": "VTRS braces for Q2 results as branded drug growth in Europe and China offsets generic headwinds in North America.",
    "url": "https://finnhub.io/api/news?id=4013bc39c3a837ec59ef8f70ab57b3ba7fc4ee3357487bf66a2ccfc415059d90",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754330820,
      "headline": "Viatris Poised to Report Q2 Earnings: What's in Store for the Stock?",
      "id": 136205894,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "VTRS braces for Q2 results as branded drug growth in Europe and China offsets generic headwinds in North America.",
      "url": "https://finnhub.io/api/news?id=4013bc39c3a837ec59ef8f70ab57b3ba7fc4ee3357487bf66a2ccfc415059d90"
    }
  },
  {
    "ts": null,
    "headline": "Why Johnson & Johnson Stock Still Has Room To Run",
    "summary": "Johnson & Johnson's stock still has room to rise after the recent financial results exceeded expectations. Learn how J&J is positioned for success.",
    "url": "https://finnhub.io/api/news?id=f91fa708d468ed0055cf208a7e499c4baab6bc95d328e2fd9c2318d48af28388",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754327543,
      "headline": "Why Johnson & Johnson Stock Still Has Room To Run",
      "id": 136202830,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/505129430/image_505129430.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Johnson & Johnson's stock still has room to rise after the recent financial results exceeded expectations. Learn how J&J is positioned for success.",
      "url": "https://finnhub.io/api/news?id=f91fa708d468ed0055cf208a7e499c4baab6bc95d328e2fd9c2318d48af28388"
    }
  },
  {
    "ts": null,
    "headline": "Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?",
    "summary": "Let's look at five pharma and biotech companies, PFE, LLY, AMGN, GILD and NVO, which are scheduled to release their second-quarter 2025 results this week.",
    "url": "https://finnhub.io/api/news?id=883190f0e2f70a7ee2c2c89d4029b1a0d3a68266fb7467a0b0963edd4dee601a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754322480,
      "headline": "Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?",
      "id": 136200228,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Let's look at five pharma and biotech companies, PFE, LLY, AMGN, GILD and NVO, which are scheduled to release their second-quarter 2025 results this week.",
      "url": "https://finnhub.io/api/news?id=883190f0e2f70a7ee2c2c89d4029b1a0d3a68266fb7467a0b0963edd4dee601a"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Reports Earnings Soon. The Stock Is Slumping for a Reason.",
    "summary": "The drug maker reports second-quarter earnings Tuesday, and investors continue to eye a list of glaring problems.",
    "url": "https://finnhub.io/api/news?id=d6e7711f96fa5c821cc98ba9bc3d735afe1c93d587d45181dc8f5cc489ab745e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754321160,
      "headline": "Pfizer Reports Earnings Soon. The Stock Is Slumping for a Reason.",
      "id": 136200400,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The drug maker reports second-quarter earnings Tuesday, and investors continue to eye a list of glaring problems.",
      "url": "https://finnhub.io/api/news?id=d6e7711f96fa5c821cc98ba9bc3d735afe1c93d587d45181dc8f5cc489ab745e"
    }
  },
  {
    "ts": null,
    "headline": "Why Investors Need to Take Advantage of These 2 Medical Stocks Now",
    "summary": "The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.",
    "url": "https://finnhub.io/api/news?id=554b7cb81af1a9789dae90b00c05f823e1d1cf6e29b8b74f9db24b75f38379f9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754312403,
      "headline": "Why Investors Need to Take Advantage of These 2 Medical Stocks Now",
      "id": 136198713,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.",
      "url": "https://finnhub.io/api/news?id=554b7cb81af1a9789dae90b00c05f823e1d1cf6e29b8b74f9db24b75f38379f9"
    }
  },
  {
    "ts": null,
    "headline": "Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas",
    "summary": "As America's population ages, chronic and rare diseases are emerging as a pressing healthcare challenge — one that disproportionately affects older adults. With more than 30 million Americans living with a rare disease, the need for accurate diagnoses and effective treatments is growing urgent. Many of these conditions remain without FDA-approved therapies, and symptoms in seniors are often misattributed to typical aging, leading to years-long diagnostic delays. Recognizing this crisis, the Trum",
    "url": "https://finnhub.io/api/news?id=871bf0ffcbc0ded573fd4e67ce5cf9a0b951f3012c64f0c0f43e2dadd96a7a2c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754310600,
      "headline": "Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas",
      "id": 136197991,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "As America's population ages, chronic and rare diseases are emerging as a pressing healthcare challenge — one that disproportionately affects older adults. With more than 30 million Americans living with a rare disease, the need for accurate diagnoses and effective treatments is growing urgent. Many of these conditions remain without FDA-approved therapies, and symptoms in seniors are often misattributed to typical aging, leading to years-long diagnostic delays. Recognizing this crisis, the Trum",
      "url": "https://finnhub.io/api/news?id=871bf0ffcbc0ded573fd4e67ce5cf9a0b951f3012c64f0c0f43e2dadd96a7a2c"
    }
  },
  {
    "ts": null,
    "headline": "BioNTech Stock Rises as Drugmaker Beats Earnings Expectations.",
    "summary": "BioNTech  stock was rising after the drugmaker reported better-than-expected results early Monday.  The company’s second-quarter loss came in at 1.60 euros per share on revenue of €261 million ($302.1 million), beating analysts’ expectations of a loss per share of €2.28 on revenue of €151 million, according to FactSet.  Revenue doubled from €129 million a year ago, driven by its Covid-19 collaboration with  Pfizer  the drugmaker said.",
    "url": "https://finnhub.io/api/news?id=43c90363f68f283e8abf53f1e299622eaf5cd70251c60ead670a0f1fb8579aed",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754308740,
      "headline": "BioNTech Stock Rises as Drugmaker Beats Earnings Expectations.",
      "id": 136198069,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "BioNTech  stock was rising after the drugmaker reported better-than-expected results early Monday.  The company’s second-quarter loss came in at 1.60 euros per share on revenue of €261 million ($302.1 million), beating analysts’ expectations of a loss per share of €2.28 on revenue of €151 million, according to FactSet.  Revenue doubled from €129 million a year ago, driven by its Covid-19 collaboration with  Pfizer  the drugmaker said.",
      "url": "https://finnhub.io/api/news?id=43c90363f68f283e8abf53f1e299622eaf5cd70251c60ead670a0f1fb8579aed"
    }
  },
  {
    "ts": null,
    "headline": "How To Earn $500 A Month From Pfizer Stock Ahead Of Q2 Earnings",
    "summary": "Pfizer Inc. (NYSE:PFE) will release earnings results for the second quarter before the opening bell on Tuesday, Aug. 5. Analysts expect the pharmaceutical company to report quarterly earnings of 57 cents per share, down from 60 cents per share in the year-ago period. Pfizer projects to report quarterly revenue of $13.53 billion, compared to $13.28 billion a year earlier, according to data from Benzinga Pro. Some investors may be eyeing potential gains from the company's dividends. Currently, Pfi",
    "url": "https://finnhub.io/api/news?id=f54e8648512153b3dcb4fe5cc0b99c52a57945cb52af3ed6f5b5ea840e503e17",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754308509,
      "headline": "How To Earn $500 A Month From Pfizer Stock Ahead Of Q2 Earnings",
      "id": 136198070,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. (NYSE:PFE) will release earnings results for the second quarter before the opening bell on Tuesday, Aug. 5. Analysts expect the pharmaceutical company to report quarterly earnings of 57 cents per share, down from 60 cents per share in the year-ago period. Pfizer projects to report quarterly revenue of $13.53 billion, compared to $13.28 billion a year earlier, according to data from Benzinga Pro. Some investors may be eyeing potential gains from the company's dividends. Currently, Pfi",
      "url": "https://finnhub.io/api/news?id=f54e8648512153b3dcb4fe5cc0b99c52a57945cb52af3ed6f5b5ea840e503e17"
    }
  },
  {
    "ts": null,
    "headline": "Central Bank Outlook Lifts Wall Street Pre-Bell; Asia, Europe Up",
    "summary": "Wall Street futures pointed moderately higher pre-bell Monday as traders weighed odds that the Feder",
    "url": "https://finnhub.io/api/news?id=00f5597fd509970a0aa122ae34451d3f2c148ce5ac685713d4231e5e774389a4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754305852,
      "headline": "Central Bank Outlook Lifts Wall Street Pre-Bell; Asia, Europe Up",
      "id": 136197847,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Wall Street futures pointed moderately higher pre-bell Monday as traders weighed odds that the Feder",
      "url": "https://finnhub.io/api/news?id=00f5597fd509970a0aa122ae34451d3f2c148ce5ac685713d4231e5e774389a4"
    }
  },
  {
    "ts": null,
    "headline": "These 4 Measures Indicate That Pfizer (NYSE:PFE) Is Using Debt Reasonably Well",
    "summary": "Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...",
    "url": "https://finnhub.io/api/news?id=a38c572c2a5598505ef05977016ceb47610bf2986101a8d6f73d3bc30f3fac1e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754305219,
      "headline": "These 4 Measures Indicate That Pfizer (NYSE:PFE) Is Using Debt Reasonably Well",
      "id": 136198072,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...",
      "url": "https://finnhub.io/api/news?id=a38c572c2a5598505ef05977016ceb47610bf2986101a8d6f73d3bc30f3fac1e"
    }
  },
  {
    "ts": null,
    "headline": "Option Volatility And Earnings Report For Aug 4 - 8",
    "summary": "It’s another big week on the earnings front this week with some important companies set to report including Palantir, Advanced Micro Devices, Uber Technologies, Pfizer, Disney, Shopify, Arista Networks and McDonald’s.",
    "url": "https://finnhub.io/api/news?id=e0aa7a5a7ff565bbf64ffc2bfd8d3525531d93efd142d335db2f4f3412c19403",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754305202,
      "headline": "Option Volatility And Earnings Report For Aug 4 - 8",
      "id": 136197889,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "It’s another big week on the earnings front this week with some important companies set to report including Palantir, Advanced Micro Devices, Uber Technologies, Pfizer, Disney, Shopify, Arista Networks and McDonald’s.",
      "url": "https://finnhub.io/api/news?id=e0aa7a5a7ff565bbf64ffc2bfd8d3525531d93efd142d335db2f4f3412c19403"
    }
  },
  {
    "ts": null,
    "headline": "BioNTech's Q2 revenues double on higher COVID vaccine sales",
    "summary": "FRANKFURT (Reuters) -German biotech firm BioNTech on Monday said that second-quarter revenues more than doubled to 261 million euros  ($302 million), driven by higher revenues from its COVID-19 vaccine collaboration with Pfizer.  The company's quarterly net loss came in at 387 million euros, an improvement over a net loss of 808 million in the year-earlier period, which at the time was burdened by provisions for a settlement with the U.S. National Institutes of Health over vaccine royalty payments.  BioNTech reiterated its guidance for 2025 revenues of 1.7 billion to 2.2 billion euros, down from 2.75 billion last year.",
    "url": "https://finnhub.io/api/news?id=197fd17cc982d19013cdee81d234da00e95c6be15a562bd1f403a5d5e5b75c77",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754304693,
      "headline": "BioNTech's Q2 revenues double on higher COVID vaccine sales",
      "id": 136198074,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "FRANKFURT (Reuters) -German biotech firm BioNTech on Monday said that second-quarter revenues more than doubled to 261 million euros  ($302 million), driven by higher revenues from its COVID-19 vaccine collaboration with Pfizer.  The company's quarterly net loss came in at 387 million euros, an improvement over a net loss of 808 million in the year-earlier period, which at the time was burdened by provisions for a settlement with the U.S. National Institutes of Health over vaccine royalty payments.  BioNTech reiterated its guidance for 2025 revenues of 1.7 billion to 2.2 billion euros, down from 2.75 billion last year.",
      "url": "https://finnhub.io/api/news?id=197fd17cc982d19013cdee81d234da00e95c6be15a562bd1f403a5d5e5b75c77"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: Earnings Meet Pressure (Rating Upgrade)",
    "summary": "Pfizer's strong EPS surprise streak and positive earnings revisions are encouraging, but patent cliff risks remain a major concern for future growth.",
    "url": "https://finnhub.io/api/news?id=a0ca4ce59099e149aa45b527ce32c5ddf9db1427234be496ad1a9fa93738ac0b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754299239,
      "headline": "Pfizer: Earnings Meet Pressure (Rating Upgrade)",
      "id": 136197650,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1292440985/image_1292440985.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer's strong EPS surprise streak and positive earnings revisions are encouraging, but patent cliff risks remain a major concern for future growth.",
      "url": "https://finnhub.io/api/news?id=a0ca4ce59099e149aa45b527ce32c5ddf9db1427234be496ad1a9fa93738ac0b"
    }
  },
  {
    "ts": null,
    "headline": "McDonald’s Earnings, New Tariff Deadline, PMIs: What to Watch This Week",
    "summary": "Earnings season marches on, with results from Walt Disney and McDonald’s among this week's highlights, along with President Trump's new tariff-hike deadline for many countries. Trump also said he would name replacements this week for Federal Reserve governor Adriana Kugler and Bureau of Labor Statistics chief Erika McEntarfer.",
    "url": "https://finnhub.io/api/news?id=357fe8439746b1683e0cb3fb265a57fca8ef5ee3066bdb81b56ce8f3a7c70d42",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754295821,
      "headline": "McDonald’s Earnings, New Tariff Deadline, PMIs: What to Watch This Week",
      "id": 136197898,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Earnings season marches on, with results from Walt Disney and McDonald’s among this week's highlights, along with President Trump's new tariff-hike deadline for many countries. Trump also said he would name replacements this week for Federal Reserve governor Adriana Kugler and Bureau of Labor Statistics chief Erika McEntarfer.",
      "url": "https://finnhub.io/api/news?id=357fe8439746b1683e0cb3fb265a57fca8ef5ee3066bdb81b56ce8f3a7c70d42"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer (PFE) Reports Earnings Tomorrow: What To Expect",
    "summary": "Global pharmaceutical company Pfizer (NYSE:PFE) will be announcing earnings results this Tuesday before market open. Here’s what to look for.",
    "url": "https://finnhub.io/api/news?id=3b786b059d79dec9c5a596557c15aa4b07ca44acc93f97282e07f6dda2b164ec",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754276922,
      "headline": "Pfizer (PFE) Reports Earnings Tomorrow: What To Expect",
      "id": 136195540,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Global pharmaceutical company Pfizer (NYSE:PFE) will be announcing earnings results this Tuesday before market open. Here’s what to look for.",
      "url": "https://finnhub.io/api/news?id=3b786b059d79dec9c5a596557c15aa4b07ca44acc93f97282e07f6dda2b164ec"
    }
  }
]